MaxWell Biomedical

MaxWell Biomedical

MaxWell Biomedical Inc. is a medical device company headquartered in San Diego. The firm was founded to address atrial fibrillation (AF) as a progressive structural disease, not merely an electrical disorder. Its wealth origin is not publicly disclosed. MaxWell's core product, the Rhythm360 system, delivers Cardiac Resynchronization Therapy for the Atrium (CRT-A). The therapy is non-destructive and aims to restore coordinated atrial contraction lost to AF remodeling. The target populations include post-open-heart surgery AF patients and those with AF and heart failure with preserved ejection fraction (HFpEF). The firm's strategy combines inter-cardiac monitoring with physiology-guided stimulation to preempt triggers. Five scientific abstracts from MaxWell were accepted at EHRA and Heart Rhythm Society 2026 (per the firm, 2026). MaxWell recently closed a new financing round—the amount and investors are undisclosed. The company employs a team whose size is not public; its sole known office is in San Diego. There are no disclosed philanthropic vehicles or operating businesses. The firm's structural differentiator is its focus on atrial mechanical recovery rather than ablation or pharmacological rhythm control. CRT-A is positioned as a new class of therapy analogous to ventricular cardiac resynchronization but applied to the atrium, avoiding tissue destruction. No current device targets both rhythm and mechanical function.